28 / 70
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 5, September/October 2016
298
AFRICA
22. Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio
A. Mg
2
+
–Ca
2
+
interaction in contractility of vascular smooth muscle:
Mg
2
+
versus organic calcium channel blockers on myogenic tone
and agonist-induced responsiveness of blood vessels.
Can J Physiol
Pharmacol
1987;
65
: 729–745.
23. Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclamp-
sia: a brief review.
Stroke
2009;
40
(4): 1169–1175.
24. Yener AU, Ozkan T, Cicek MC, Baysal E, Dogan E, Cicek OF,
et al
.
Magnesium; the electrolyte that delays the formation of atrial fibrilla-
tion.
Exp Clin Cardiol
2014;
20
(1): 2624–2633.
25. Vigorito C, Giordano A, Ferraro P, Acanfora D, De Caprio L, Naddeo
C,
et al
. Hemodynamic effects of magnesium sulfate on the normal
human heart.
Am J Cardiol
1991;
67
(16): 1435–1437.
26. Resnick LM, Gupta RK, DiFabio B, Barbagallo M, Mann S, Marion R,
et al
. Intracellular ionic consequences of dietary salt loading in essential
hypertension. Relation to blood pressure and effects of calcium channel
blockade.
J Clin Invest
1994;
94
(3): 1269–1276.
27. Cunningham J, Rodrıguez M, Messa P. Magnesium in chronic kidney
disease Stages 3 and 4 and in dialysis patients.
Clin Kidney J
2012;
5
(Suppl 1): i39–i51.
28. Randell EW, Mathews M, Gadag V, Zhang H, Sun G. Relationship
between serum magnesium values, lipids and anthropometric risk
factors.
Atherosclerosis
2008;
196
: 413–419.
Confidence Through Clinical
and Real World Experience
1-3
Millions of Patients Treated Across Multiple Indications
4
#1 NOAC prescribed by Cardiologists
*
References:
1.
Patel M.R., Mahaffey K.W., Garg J.
et al.
Rivaroxaban versus warfarin in non-valvular atrial fibrillation.
N Engl J Med
. 2011;365(10):883–91.
2.
Tamayo S., Peacock W.F., Patel M.R.,
et al.
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8.
3.
Camm A.J., Amarenco P., Haas S.
et al.
XANTUS: A Real-World,
Prospective, Observational Study.
4.
Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.
For fullprescribing information,refer to thepackage insertapprovedby theMedicinesRegulatoryAuthority (MCC). S4 XARELTO
®
10 (Film-coated tablets)
.Reg.No.:42/8.2/1046.Eachfilm-coated tabletcontainsrivaroxaban10mg.
PHARMACOLOGICALCLASSIFICATION:
A.8.2Anticoagulants.
INDICATION:
Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. S4 XARELTO
®
15 and XARELTO
®
20 (Film-coated tablets). Reg. No.: XARELTO
®
15: 46/8.2/0111; XARELTO
®
20: 46/8.2/0112. Each film
coated tablet contains rivaroxaban 15 mg (XARELTO
®
15) or 20 mg (XARELTO
®
20).
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2)
Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).
HCR:
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM.01.2016.1265
*Impact RX Data Oct - Dec 2015
NOAC: Non Vitamin K Oral Anticoagulant